| Name | Title | Contact Details |
|---|
Farmers Life Insurance Company ("Farmers Life") was founded in 1997 as a small credit life and disability insurance company and has flourished by providing secure insurance products that address a growing number of diverse consumer needs. In a fast-paced industry, we strive to deliver best-in-class service throughout the life of our policies ensuring that people can fund their retirements, secure their legacies and enjoy the peace of mind associated with a well-planned future.
Weve run the gambit on virtually everything you can do with an automobile. From donuts at Tire Slayer Studios to gravity-defying stunts on the streets of Las Vegas, weve earned our stripes on the automotive front lines, the pits, and the winners podium. Its a sense of pride and passion that allows us to continue to push the boundaries that make us who we are. At our core, we are enthusiasts just like our customers. We connect with our fans in a way most brands cant imagine. Because at one time, we, too, were just enthusiasts pursuing our passion for automotive culture and watching our motorsport heroes from the grandstands.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.